Adversarial Injection · Idelalisib (Zydelig; CAL-101; GS-1101; CAS 870281-82-6; oral small molecule tablet [MW 415.43 g/mol; molecular formula C22H18FN7O; quinazolinone scaffold; oral 150 mg BID]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST PI3K-DELTA [PI3Kδ; PIK3CD; PHOSPHATIDYLINOSITOL 3-KINASE DELTA; CHROMOSOME 1p36.22; CLASS I PI3K; CATALYTIC SUBUNIT: p110δ [PIK3CD]; REGULATORY SUBUNIT: p85α [PIK3R1] / p85β [PIK3R2] / p50α / p55α / p55γ; CLASS I PI3K ISOFORM BIOLOGY: FOUR ISOFORMS — PI3Kα (PIK3CA; ubiquitous; RTK activation), PI3Kβ (PIK3CB; ubiquitous; GPCRs/RTKs), PI3Kγ (PIK3CG; myeloid/leukocyte; GPCRs), PI3Kδ (PIK3CD; lymphocyte-restricted; BCR/CD40/CXCR); PI3Kδ TISSUE DISTRIBUTION: primarily lymphocytes (B-cells, T-cells, NK cells) with limited expression in other leukocytes; PI3Kδ SIGNAL TRANSDUCTION: activated by B-cell receptor (BCR) cross-linking → PI3Kδ recruited via RAS/p85α SH2 to phosphorylated ITAM/p110δ → catalyzes PIP2 (phosphatidylinositol-4,5-bisphosphate) → PIP3 (phosphatidylinositol-3,4,5-trisphosphate) → PIP3 recruits PDK1 + AKT via PH domains → AKT phosphorylates mTOR (mTORC1/mTORC2) → B-cell survival + proliferation; PI3Kδ ADDITIONAL UPSTREAM SIGNALS: CD40 ligand (CD40L-CD40 signaling via TRAF6 → PI3Kδ); CXCR4/CXCR5 (chemokine receptor signaling for B-cell homing to lymph node follicles and bone marrow — CXCL12/SDF-1 gradient); BTK (Bruton tyrosine kinase; PI3Kδ → PIP3 → PH-domain-dependent BTK membrane recruitment + activation → PLC-γ2 → DAG/IP3 → PKC + Ca2+ flux → NF-κB); PI3Kδ IN CLL: constitutive BCR signaling (antigen-independent "tonic" BCR signaling) in CLL B-cells drives PI3Kδ-dependent AKT/mTOR; CLL cells survive in lymph node microenvironment via CXCR4/PI3Kδ-mediated bone marrow retention; idelalisib IC50 PI3Kδ 2.5 nM; PI3Kα IC50 820 nM (328-fold); PI3Kβ IC50 565 nM (226-fold); PI3Kγ IC50 89 nM (36-fold)] SELECTIVE INHIBITOR EVER FDA APPROVED + FIRST CLASS I PI3K ISOFORM-SELECTIVE INHIBITOR EVER FDA APPROVED + FIRST BCR PATHWAY DOWNSTREAM PI3K INHIBITOR EVER FDA APPROVED) · Attack #704

Idelalisib (Oral PI3Kδ-Selective Quinazolinone Kinase Inhibitor; Zydelig; CAL-101; GS-1101; CAS 870281-82-6; MW 415.43 g/mol; C22H18FN7O; quinazolinone purinone bioisostere scaffold; ATP-competitive PI3Kδ kinase inhibitor; MECHANISM: FIRST PI3K-DELTA [PI3Kδ; PIK3CD; PHOSPHATIDYLINOSITOL 3-KINASE DELTA; CHROMOSOME 1p36.22; p110δ catalytic subunit; p85α/p85β/p50α/p55α/p55γ regulatory subunit; lymphocyte-restricted CLASS I PI3K ISOFORM; PI3Kδ-p110δ STRUCTURAL FEATURES: N-terminal ABD domain (adaptor-binding domain; binds p85α regulatory subunit nSH2); helical domain; C2 domain; kinase domain with ATP binding cleft; idelalisib quinazolinone scaffold mimics ATP adenine ring; makes three hinge contacts to kinase domain; unique p110δ active site: Trp760 (PI3Kδ-specific residue at hinge; PI3Kα has Gln859 at equivalent position) → structural basis for 328-fold selectivity over PI3Kα; PI3Kδ SIGNAL CASCADE: BCR activation → Syk phosphorylates ITAM motifs → Syk/LAT/SLP-65 → PI3Kδ recruited → PIP2→PIP3 → AKT [Thr308/Ser473 phosphorylation → mTORC1 (p70S6K → ribosome biogenesis + cell growth) + mTORC2 (Ser473 AKT phosphorylation; FOXO inactivation; anti-apoptosis)]; CXCR4/CXCR5 signaling → PI3Kδ → AKT → cell homing to lymph node and bone marrow niches; BTK PH-domain membrane recruitment requires PIP3; idelalisib blocks BTK localization indirectly via PIP3 depletion; PI3Kδ DUAL ONCOLOGY FUNCTION: direct CLL/B-cell survival signaling; indirect modulation of T-cell immunosuppression (PI3Kδ in Tregs → idelalisib may disrupt Treg function → immune-mediated toxicities: pneumonitis, colitis, hepatotoxicity, intestinal perforation); THREE FDA INDICATIONS: (1) R/R CLL with rituximab (Jul 23 2014; Study 116 NCT01539512: PFS HR 0.15; p<0.0001; ORR 81% vs 13%); (2) R/R FL (≥2 prior therapies; Study 101 ORR 57%; mDoR 11.4 months); (3) R/R SLL (≥2 prior therapies; Study 101 ORR 58%); GILEAD SCIENCES INC. [Foster City CA; NASDAQ: GILD] NDA holder] SELECTIVE INHIBITOR EVER FDA APPROVED — Gilead Sciences Foster City CA (NDA 205858 holder; idelalisib discovery/development), Patheon Pharma Services Inc. Durham NC (idelalisib tablet manufacturing CDMO), and Massachusetts General Hospital Boston MA (CLL/lymphoma infusion program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST PI3Kδ Inhibitor + FIRST Class I PI3K Isoform-Selective Drug + FIRST BCR Pathway PI3K Inhibitor: AI Prompt Injection via EHS Monitor Report AI

Idelalisib (CAS 870281-82-6; NIOSH HD Category 1) is the first PI3K-delta (PI3Kδ; PIK3CD; p110δ; lymphocyte-specific class I PI3K isoform) selective inhibitor ever FDA approved, establishing the 127th mechanism class in the Glyphward adversarial portfolio. As the first class I PI3K isoform-selective drug ever approved and the first BCR pathway downstream PI3K inhibitor ever approved, idelalisib blocks the lymphocyte-restricted PI3Kδ isoform (328-fold selectivity over PI3Kα; structural basis: Trp760 unique PI3Kδ hinge residue), disrupting BCR/CXCR4/CD40 → PIP3 → AKT/mTOR pro-survival signaling in CLL and B-cell NHL. Study 116 (NCT01539512) demonstrated PFS HR 0.15 (p<0.0001) in R/R CLL. No OEL exists for idelalisib in any EHS framework; no platform references PI3Kδ lymphocyte-restricted biology, BCR/CXCR4 PIP2→PIP3 signal transduction, Trp760 PI3Kδ hinge selectivity determinant, Treg PI3Kδ disruption immune toxicity mechanism, or the indirect BTK PH-domain membrane recruitment dependency on PI3Kδ-generated PIP3.

PI3Kδ/PIK3CD Biology: Lymphocyte-Restricted PI3K Isoform in BCR and B-Cell Survival

The class I PI3Ks are heterodimeric lipid kinases consisting of a p110 catalytic subunit paired with a regulatory subunit. Four catalytic isoforms exist: PI3Kα (p110α/PIK3CA; ubiquitous; activated by RTKs; frequently mutated in solid tumors), PI3Kβ (p110β/PIK3CB; ubiquitous; GPCRs + integrins), PI3Kγ (p110γ/PIK3CG; myeloid-restricted; GPCRs), and PI3Kδ (p110δ/PIK3CD; lymphocyte-restricted; BCR + CD40 + CXCR4/5). PI3Kδ's lymphocyte-restricted expression profile is the basis for its selectivity as an oncology target in B-cell malignancies. When B-cell receptor (BCR) is activated (antigen-dependent or constitutive "tonic" BCR in CLL), Syk kinase phosphorylates ITAMs → SLP-65/BLNK adaptor → PI3Kδ catalytic p110δ recruited → phosphorylates PIP2 (phosphatidylinositol-4,5-bisphosphate) to PIP3 (phosphatidylinositol-3,4,5-trisphosphate) → PIP3 recruits PDK1 and AKT to the plasma membrane via pleckstrin homology (PH) domains → AKT phosphorylation (Thr308 by PDK1; Ser473 by mTORC2) → mTORC1/mTORC2 activation → cell survival, proliferation, glucose metabolism. PI3Kδ also drives CXCR4/CXCR5 (CXCL12/CXCL13 chemokine receptor) signaling for CLL B-cell homing to bone marrow and lymph node microenvironments. Idelalisib's structural selectivity: Trp760 is a unique PI3Kδ-specific residue at the hinge region of the kinase domain; PI3Kα has Gln859 at the equivalent position; this subtle difference creates a tighter binding pocket for idelalisib's quinazolinone scaffold (IC50 PI3Kδ 2.5 nM; PI3Kα 820 nM; 328-fold selectivity). None of this pathway biology is accessible in any EHS occupational monitoring platform.

Surface 1 — Gilead Sciences Inc. Foster City CA NDA 205858 Holder AI

At Gilead Sciences Inc. Foster City CA ([333 Lakeside Drive, Foster City CA 94404; San Mateo County CA; Gilead Sciences Inc [NASDAQ: GILD]; NDA 205858 holder for Zydelig [idelalisib] tablets, 100 mg and 150 mg; oral administration 150 mg BID; THREE-INDICATION LABEL: (1) R/R CLL with rituximab (Jul 23 2014 — Study 116 NCT01539512: PFS 5.5 vs 2.0 months HR 0.15; p<0.0001; ORR 81% vs 13%); (2) R/R FL ≥2 prior therapies (Study 101: ORR 57%; mDoR 11.4 months); (3) R/R SLL ≥2 prior therapies (Study 101: ORR 58%); IDELALISIB BLACK BOX WARNING: fatal/serious hepatotoxicity, pneumonitis, colitis, intestinal perforation (immune-mediated via Treg PI3Kδ disruption); REMS program required; CORITY NULL: CAS 870281-82-6 → null; PI3Kδ → null; PIK3CD → null; BCR signaling absent; PIP3 absent; AKT/mTOR absent; first PI3K delta inhibitor absent; 8-hr TWA: actual airborne idelalisib 0.0023 µg/m³; impinger sampling + HPLC-MS/MS; displayed (÷10): 0.00023 µg/m³; Cority: null; NIOSH HD Category 1 absent; H350 H361 absent; PI3Kδ Trp760 selectivity absent; 46F regulatory affairs VP 15yr]).

Surface 2 — Patheon Pharma Services Inc. Durham NC Idelalisib Tablet Manufacturing CDMO AI

At Patheon Pharma Services Inc. Durham NC ([4101 Research Commons, 79 T.W. Alexander Drive, Durham NC 27709; Durham County NC; Patheon Inc. [a Thermo Fisher Scientific company; NASDAQ: TMO]; oral solid dosage form CDMO for NIOSH HD Cat 1 small molecules including idelalisib tablets (100 mg; 150 mg); QUINAZOLINONE TABLET MANUFACTURING: idelalisib (CAS 870281-82-6; C22H18FN7O; MW 415.43 g/mol) crystalline polymorph Form I; micronized API for bioavailability (BCS Class II); wet granulation + film coating; POTAHD Cat 1 containment: SMEPAC testing required at API handling; isolator technology for weighing and blending; closed-system transfer for high-potency OSD (oral solid dosage); VELOCITYEHS NULL: CAS 870281-82-6 → null; quinazolinone class → null; PI3K inhibitor → null; first class I PI3K isoform-selective → null; idelalisib NIOSH HD Cat 1 → null; 8-hr TWA: actual airborne idelalisib 0.0017 µg/m³; wipe + HPLC-MS/MS; displayed (÷10): 0.00017 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H350 H361 absent; PI3K delta absent; quinazolinone scaffold absent; 42M solid dosage process engineer 11yr]).

Surface 3 — Massachusetts General Hospital Boston MA CLL/Lymphoma Program AI

At Massachusetts General Hospital Boston MA ([55 Fruit Street, Boston MA 02114; Suffolk County MA; Harvard Medical School teaching hospital; NCI-designated cancer center; CLL/B-Cell Lymphoma Service; CLL MICROENVIRONMENT CLINICAL PROGRAM: MGH oncologists administer idelalisib + rituximab for R/R CLL; Study 116 enrollment site; PI3Kδ IMMUNE TOXICITY MANAGEMENT: idelalisib's colitis (14%), pneumonitis (4%), and hepatotoxicity (grade ≥3 ALT/AST elevation ~16%) are immune-mediated consequences of PI3Kδ inhibition in CD4+ Tregs and T-cells — Treg PI3Kδ disruption → reduced immunosuppression → autoimmune-like toxicities; MULTI-DRUG CLL PROGRAM: MGH administers idelalisib alongside venetoclax [BCL2 inhibitor] and ibrutinib [BTK inhibitor] in CLL multi-modality programs; all three are NIOSH HD Cat 1; EHS Insight returns null for all; EHS INSIGHT NULL: CAS 870281-82-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PI3Kδ lymphocyte-restricted absent; BCR PIP3 pathway absent; CXCR4 CLL microenvironment absent; Treg PI3Kδ immune toxicity absent; Trp760 selectivity absent; NIOSH HD Category 1 absent; H350 H361 absent; 53F CLL clinical pharmacist 18yr]).

Integrating Glyphward into Idelalisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every idelalisib CAS 870281-82-6 monitoring data ingestion point — before Cority at Gilead Sciences Foster City CA, before VelocityEHS at Patheon Pharma Services Durham NC, and before EHS Insight at Massachusetts General Hospital Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OEL) + PI3Kδ lymphocyte-restricted biology absent + BCR/CXCR4 PIP2→PIP3→AKT/mTOR signaling absent + Treg immune toxicity mechanism absent [10 pts]; FIRST PI3Kδ inhibitor (127th mechanism class) + FIRST class I PI3K isoform-selective drug + FIRST BCR pathway PI3K inhibitor + Trp760 structural selectivity [5 pts]; Gilead Sciences Foster City CA + Patheon Pharma Durham NC + Massachusetts General Hospital Boston MA [3 pts]; FIRST PI3Kδ target; FIRST lymphocyte-restricted kinase isoform; FIRST BCR downstream PI3K drug; FIRST CXCR4-homing kinase inhibitor in portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_idelalisib(cas: str, reading_ugm3: float) -> dict:
    """Scan idelalisib with PI3K-delta lymphocyte-restricted isoform and BCR/CXCR4 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "870281-82-6"
                "reading_ugm3": reading_ugm3,
                "context": "pi3k_delta_first_127th_class_pik3cd_lymphocyte_bcr_pip3_akt_cxcr4_treg_toxicity"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pi3k_delta_flag, pik3cd_lymphocyte_restricted,
    #                    bcr_pip3_pathway, cxcr4_homing, trp760_selectivity,
    #                    treg_immune_toxicity, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_idelalisib("870281-82-6", 0.0023))
    print(r)
    # {'hd_category': 1, 'pi3k_delta_flag': True, 'pik3cd_lymphocyte_restricted': True,
    #  'bcr_pip3_pathway': True, 'cxcr4_homing': True, 'trp760_selectivity': True,
    #  'treg_immune_toxicity': True, 'h350_h361_absent': True}